……………… ii Supplement Table S2 ……………… iii ii Supplement Tables   Table S1. Patient clinical data of MD-derived clusters and diametric extreme patients indicated in Figure 4 . Columns 1 and 2 contain additional information regarding the two patient clusters identified by unsupervised clustering of the 2130 MD scores from deregulated pathways in at least one patient (Methods 2.8). Columns 3 and 4 present clinically relevant information for the diametric extreme phenotypes (TGCA breast cancer, RNA--seq, Dataset II, Table 1 ). iii Table S2 . Ranked predictive pathway signatures identified using Support Vector Machine (SVM).
Utilizing the pathway MD CRMs in a different manner, a binary classification ('good' versus 'poor' prognosis) model for the 80 breast cancer patients in Dataset II, Table 1 was constructed using svm in the e1071 R package. 20 out of 80 patients were given a 'good' clinical outcome, defined by disease-free patients surviving more than 2.5 years. The features were the 2130 MD CRMs for pathways found deregulated in at least one patient. A linear kernel was specified and leave-on-out cross-validation (CV) was used to tune the cost parameter. The model with the lowest CV error rate (0.25) was retained. 57 patients were labeled as the support vectors or in the margin. Weights were assigned to each feature by multiplying the SVM model coefficients times the features from the 57 patients. The features (pathways) were ranked by absolute value of the weights. The top 20 pathways are listed below: Figure S2 . MD and Wilcoxon methods exhibit bias towards finding larger genesets deregulated, but not towards higher intensity or longer genes. We examined the relationship between identifying a geneset deregulated and the typical gene intensity, gene length, and number of genes within the 3243 GO-BP terms studied. For each quantity of interest, we computed a reference distribution, "All Pathways." This is the distribution of the values for all pathways regardless of deregulation status. (A) Gene length analysis. We computed gene lengths using the UCSC Genome Browser (vers. hg19) by subtracting the end position from the start position. Then we summarized the gene length by finding the median of the log2 gene lengths within the pathway. Using Dataset II (Table 1) , the distributions of log2 median gene lengths of the deregulated pathways identified by both methods were found. Both methods are slightly more peaked and less variable than the reference distribution. There is not a bias towards longer genes as reported for some geneset tests (Young, et al., 2010) . (B) Gene intensity analysis. A measure of pathway gene intensity was assigned to each GO-BP term by first averaging the gene expression from the 80 tumor samples in Dataset II, Table 1 . Then find the median average gene expression to summarize the pathway gene intensity. Again we see that there is a tendency towards central intensity values in the pathways identified as deregulated in Dataset II, but do not observe a bias towards higher intensity as reported in other geneset methodology (Young, et al., 2010) . (C, D) Pathway size analysis. The reference distribution is all GO-BP terms with 15 to 500 genes. Panel C depicts the comparison between pathways found deregulated in the TCGA breast cancer patients, Dataset I. We see that there is a tendency to identify larger pathways deregulated. To ensure that this is an artifact of the methodology and not reflecting true biology, we employed technical replicates of breast cancer samples captured by microarray, (MAQC--II, GEO: GSE20194,Shi, et al., 2010) . We treat pairs of technical replicates as "normal" and "tumor" samples. Any identified pathways would then be considered a false positive. Indeed, we find the distribution of identified pathways in technical replicates is biased towards larger genesets. Legend: "All pathways" = reference distribution. Figure S3 . Top ten scoring pathways predict breast cancer survival. (A) The ten deregulated pathways found from the 80 breast cancer patients in Dataset II (Table 1) with highest absolute MD scores were used to produce PAM clusters based on the MD scores. Restricting to only ten pathways maintains accurate survival prediction (log-rank p-value < 0.01). (B) Similarly, the top ten Wilcoxon-ranked pathway scores produced clusters with distinct survival curves. Panels C and D display the top ranked scoring pathways for MD and Wilcoxon approaches, respectively. Table 1 dataset II) resulting in 3225 clinical importance metrics. We present the first principal component for the 1344 MD CRMs corresponding to pathways found deregulated in at least one of the 14 diametric extreme phenotypes of: (i) death of disease in less than 2.5 years (n=5) and (ii) disease-free survival for more than four years (n=9). The boxplots display a trend for higher PC1 for the worst phenotype, but the outliers in each group muddle the association (Wilcoxon p-value > 0.02). 
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